C Michael Gibson/Baim Institute
Feb 7, 2026, 14:25
C Michael Gibson: Asundexian Reduces Ischemic Stroke Without Increasing Bleeding Risk
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:
”Among patients with non-cardioembolic ischemic stroke or high-risk TIA treated with antiplatelet therapy, asundexian 50 mg reduced the occurrence of ischemic stroke (csHR 0.74; 95% CI, 0.65 to 0.84; p<0.001).
The difference between the treatment arms began early and continued throughout the treatment period.
A consistent effect was seen in subgroups.
Asundexian was associated with a reduction in disabling or fatal stroke (mRS ≥ 3)
Asundexian was not associated with an increase in bleeding Including ISTH major, CRNM, minor or intracranial bleeding.”
Stay updated with Hemostasis Today.
-
May 13, 2026, 15:19Papa Heme։ Causes of Isolated Prolonged aPTT Without Bleeding
-
May 13, 2026, 15:10Wolfgang Miesbach: Rethinking Bleeding Risk in Anticoagulation
-
May 13, 2026, 15:09Veronica Sanchez: Better Cardiovascular Health Helps Lower Heart Attack Risk
-
May 13, 2026, 15:07Tung Nguyen Thanh: New Perspective on Thrombosis in Hematological Malignancies in Vietnam
-
May 13, 2026, 15:03Haji Siyamuddin Ansari: The Key Difference Between Plasma and Serum
-
May 13, 2026, 14:45Masoabi Sefojane: The Cost of a 35-Year Diagnosis Delay
-
May 13, 2026, 14:39Ahmed Mohsen: Managing DVT During Pregnancy and Lactation
-
May 13, 2026, 14:38The Coffee Shop Origins of Factor V Leiden – ISTH
-
May 13, 2026, 14:33Moustafa Abdou: Could a Commonly Prescribed Drug Trigger Life-Threatening Hemolysis?